1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians, 68(6): 394-424. [DOI:10.3322/caac.21492]

2. Hadziahmetovic M, Shirai K, Chakravarti A (2011) Recent advancements in multimodality treatment of gliomas. Future Oncology, 7(10): 1169-83. [DOI:10.2217/fon.11.102]

3. Ahmed R, Oborski MJ, Hwang M, Lieberman FS, Mountz JM (2014) Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods. Cancer Management Research, 6: 149. [DOI:10.2147/CMAR.S54726]

4. Parvez K, Parvez A, Zadeh G (2014) The diagnosis and treatment of pseudoprogression, radiation necrosis and brain tumor recurrence. Int J Mol Sci, 15(7): 11832-46. [DOI:10.3390/ijms150711832]

5. Chowdhary MM, Ene CI, Silbergeld DL (2015) Treatment of Gliomas: How did we get here? Sur Neuro Int, 6(Suppl 1): S85. [DOI:10.4103/2152-7806.151348]

6. Raizer J, Parsa A. Current understanding and treatment of gliomas: Springer; 2015. [DOI:10.1007/978-3-319-12048-5]

7. Paolieri F, Sbrana A, Bloise F, Biasco E, Galli L (2018) Do We Need to Improve Oral Chemotherapy Adherence Monitoring? A Case Report of Temozolomide Overdose. Int J Case Rep, 2(1): 2.

8. Letarte N, Gabay MP, Bressler LR, Long KE, Stachnik JM, Villano JL (2014) Analyzing temozolomide medication errors: potentially fatal. Journal of Neuro-Oncology, 120(1): 111-5. [DOI:10.1007/s11060-014-1523-1]

9. Spence AM, Kiem H-P, Partap S, Schuetze S, Silber JR, Peterson RA (2006) Complications of a temozolomide overdose: a case report. Journal of Neuro-Oncology, 80: 57-61. [DOI:10.1007/s11060-006-9152-y]